Oncobiologics, inVentiv in Biosimilars Alliance

Oncobiologics, Inc. and inVentiv Health have entered a strategic partnership for the clinical development of Oncobiologic’s pipeline. The global partnership will initially focus on biosimilar assets, including generic versions of Humira, Rituxan, Avastin, Herceptin and Erbitux, and could be expanded to include innovative molecules. inVentiv will lead and execute clinical studies, provide bioanalytical support for trials, and may also contribute commercialization capabilities in select countries.
 
“After an exhaustive global review of potential partners, we selected the broad-scale inVentiv platform as an important differentiator for our program as this partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets. inVentiv is able to take the scope of these agreements to a much broader level by working across the full development life cycle of each biosimilar and innovator product while preparing for a successful market launch,” said Oncobiologics chief executive officer, Pankaj Mohan, Ph.D.
 
Ray Hill, president, inVentiv Health Clinical said, “We are thrilled to partner with Oncobiologics and to be a part of their highly capable biosimilars consortium.  With their recent global partnering successes, we look forward to helping Oncobiologics bring their biosimilar assets through clinical trials and into the marketplace. By joining their fully-integrated CMC capabilities with inVentiv’s broad clinical and commercial expertise, we are creating a venture that is truly greater than the sum of its parts.”